Nothing Special   »   [go: up one dir, main page]

EA201790716A1 - Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr - Google Patents

Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr

Info

Publication number
EA201790716A1
EA201790716A1 EA201790716A EA201790716A EA201790716A1 EA 201790716 A1 EA201790716 A1 EA 201790716A1 EA 201790716 A EA201790716 A EA 201790716A EA 201790716 A EA201790716 A EA 201790716A EA 201790716 A1 EA201790716 A1 EA 201790716A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fgfr
panels
detect
mutant genes
inhibitor treatment
Prior art date
Application number
EA201790716A
Other languages
English (en)
Other versions
EA037920B1 (ru
Inventor
Джаяпракаш Каркера
Сусо Хесус Платеро
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201790716A1 publication Critical patent/EA201790716A1/ru
Publication of EA037920B1 publication Critical patent/EA037920B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

В настоящем документе раскрываются способы выявления онкологического пациента, который будет поддаваться лечению ингибитором рецептора фактора роста фибробластов (FGFR), и способы лечения страдающих раком пациентов. Такие способы включают анализ биологического образца, взятого у пациента, на наличие одного или более мутантов FGFR из панели мутантных генов FGFR. В настоящем документе также раскрываются наборы и праймеры для выявления в биологическом образце наличия одного или более генов мутантов FGFR.
EA201790716A 2014-09-26 2015-09-18 Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr EA037920B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056159P 2014-09-26 2014-09-26
PCT/US2015/050996 WO2016048833A2 (en) 2014-09-26 2015-09-18 Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor

Publications (2)

Publication Number Publication Date
EA201790716A1 true EA201790716A1 (ru) 2017-10-31
EA037920B1 EA037920B1 (ru) 2021-06-07

Family

ID=54337343

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790716A EA037920B1 (ru) 2014-09-26 2015-09-18 Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr

Country Status (38)

Country Link
US (3) US20160090633A1 (ru)
EP (2) EP3198033B1 (ru)
JP (4) JP6766037B2 (ru)
KR (2) KR20220162823A (ru)
CN (2) CN113957146A (ru)
AR (1) AR102345A1 (ru)
AU (3) AU2015321626B2 (ru)
CA (1) CA2962075A1 (ru)
CO (1) CO2017003528A2 (ru)
CR (1) CR20170104A (ru)
CY (1) CY1125190T1 (ru)
DK (1) DK3198033T3 (ru)
EA (1) EA037920B1 (ru)
EC (1) ECSP17025787A (ru)
ES (1) ES2912567T3 (ru)
GT (1) GT201700059A (ru)
HR (1) HRP20220496T1 (ru)
HU (1) HUE058219T2 (ru)
IL (2) IL251264B (ru)
JO (1) JO3681B1 (ru)
LT (1) LT3198033T (ru)
MA (1) MA40761B1 (ru)
MX (2) MX392774B (ru)
MY (1) MY194567A (ru)
NI (1) NI201700035A (ru)
PH (1) PH12017500556A1 (ru)
PL (1) PL3198033T3 (ru)
PT (1) PT3198033T (ru)
RS (1) RS63178B1 (ru)
SG (1) SG11201702381QA (ru)
SI (1) SI3198033T1 (ru)
SM (1) SMT202200177T1 (ru)
SV (1) SV2017005415A (ru)
TW (1) TWI706136B (ru)
UA (1) UA122564C2 (ru)
UY (1) UY36325A (ru)
WO (1) WO2016048833A2 (ru)
ZA (1) ZA201702899B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
WO2015111716A1 (ja) 2014-01-24 2015-07-30 公益財団法人がん研究会 新規融合体及びその検出法
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
HRP20220496T1 (hr) 2014-09-26 2022-05-27 Janssen Pharmaceutica Nv Uporaba fgfr mutantnih genskih panela kod identifikacije pacijenata s rakom koji će reagirati na liječenje s inhibitorom fgfr
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US11975002B2 (en) * 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
AU2019310594A1 (en) 2018-07-27 2021-02-11 Zepto Life Technology, Inc. System and method for sample preparation in GMR-based detection of biomarkers
KR20210064274A (ko) * 2018-09-21 2021-06-02 얀센 파마슈티카 엔.브이. 담관암종의 치료
CN113423402A (zh) * 2019-02-12 2021-09-21 詹森药业有限公司 癌症治疗
CA3130460A1 (en) 2019-03-29 2020-10-08 Anne Elizabeth O'HAGAN Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CA3130773A1 (en) 2019-03-29 2020-10-08 Peter Marie Z. De Porre Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202112932QA (en) * 2019-05-31 2021-12-30 Qed Therapeutics Inc Methods of treating urinary system cancers
CN110241183B (zh) * 2019-06-13 2022-10-28 南京世和基因生物技术股份有限公司 一种fgfr融合基因的检测方法、试剂盒以及探针库
US20220307078A1 (en) * 2019-09-09 2022-09-29 Zepto Life Technology, LLC Systems and methods for detecting genetic variation in nucleic acids
JOP20220073A1 (ar) 2019-09-26 2023-01-30 Janssen Pharmaceutica Nv استخدام مثبطات fgfr في السرطانات المعدلة جينيا بـ fgfr لتحسين استجابة المريض لتحصين مثبطات نقطة الفحص في أوضاع علاجية تتابعية
AU2021220285A1 (en) 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
BR112022020846A2 (pt) * 2020-04-15 2022-12-27 Alkermes Pharma Ireland Ltd Agentes imunoestimuladores em combinação com inibidores de angiogênese
CN111440790A (zh) * 2020-05-08 2020-07-24 公安部物证鉴定中心 唾液斑迹dna和rna同时提取的方法
EP4210702A1 (en) 2020-09-14 2023-07-19 JANSSEN Pharmaceutica NV Fgfr inhibitor combination therapies
CN112143815B (zh) * 2020-11-25 2021-02-26 江苏申基生物科技有限公司 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法
MX2023013802A (es) 2021-05-19 2023-12-06 Janssen Pharmaceutica Nv Inhibidores de tirosina quinasa de fgfr para el tratamiento de tumores solidos avanzados.
MX2024004488A (es) 2021-10-12 2024-07-10 Taris Biomedical Llc Formulaciones y sistemas de erdafitinib para administración intravesical.
EP4479055A1 (en) 2022-02-18 2024-12-25 TARIS Biomedical LLC Erdafitinib formulations and osmotic systems for intravesical administration
WO2024173377A1 (en) 2023-02-13 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer
WO2024170495A1 (en) 2023-02-13 2024-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2024173716A1 (en) 2023-02-17 2024-08-22 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer
WO2025059602A1 (en) 2023-09-14 2025-03-20 Taris Biomedical Llc Methods of treating bladder cancer using intravesical administration of erdafitinib
CN119219611B (zh) * 2024-12-03 2025-04-18 南京诺源医疗器械有限公司 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
AU5214500A (en) 1999-05-05 2000-11-21 Centre National De La Recherche Scientifique (C.N.R.S.) Means for detecting and treating pathologies linked to fgfr3
AU2003300504B2 (en) 2002-10-01 2009-10-01 Epigenomics Ag Method and nucleic acids for the improved treatment of breast cell proliferative disorders
WO2004085676A1 (en) * 2003-03-26 2004-10-07 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1659175A1 (en) * 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
WO2006127926A2 (en) 2005-05-23 2006-11-30 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
BRPI0619548A2 (pt) 2005-12-08 2011-10-04 Novartis Ag efeitos inibidores de fgfr3 em transcrição de gene
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US20100075337A1 (en) 2007-02-27 2010-03-25 Diana Graus Porta Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereof
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
WO2008157801A2 (en) 2007-06-21 2008-12-24 Gen-Probe Incorporated Instrument and receptacles for performing processes
US8071338B2 (en) 2007-08-08 2011-12-06 Roche Molecular Systems, Inc. Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity
WO2013173480A1 (en) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of bladder cancer recurrence
WO2013173485A1 (en) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of bladder cancers
GB0718542D0 (en) 2007-09-22 2007-10-31 Univ Dundee Targeted modulation of gene expression
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
WO2011027219A1 (en) 2009-09-04 2011-03-10 Progenika Biopharma, S.A. High throughput detection of small genomic deletions and insertions
US9140689B2 (en) * 2010-03-14 2015-09-22 Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102293770A (zh) * 2011-05-25 2011-12-28 温州医学院 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂
CN102319224B (zh) * 2011-07-27 2013-03-20 赛乐医药科技(上海)有限公司 复方甲氧那明的速释-缓释渗透泵制剂
SG2014010276A (en) 2011-08-18 2014-03-28 Nestec Sa Compositions and methods for detecting allelic variants
US20130096021A1 (en) 2011-09-27 2013-04-18 Arul M. Chinnaiyan Recurrent gene fusions in breast cancer
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (en) * 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
ES2746288T3 (es) * 2012-02-28 2020-03-05 Astellas Pharma Inc Compuesto heterocíclico aromático que contiene nitrógeno
EP2824181B1 (en) 2012-03-08 2018-11-14 Astellas Pharma Inc. Novel fgfr3 fusion product
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014007369A1 (ja) * 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Fgfr2融合遺伝子
EP4276200A3 (en) * 2012-07-24 2024-02-14 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
RU2015102194A (ru) * 2012-07-27 2016-09-20 Дженентек, Инк. Способы лечения связанных с fgfr3 состояний
EA031631B1 (ru) * 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
AU2013337264B2 (en) * 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014113729A2 (en) * 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
US9777333B2 (en) 2013-04-05 2017-10-03 Life Technologies Corporation Gene fusion
EP3004380A2 (en) 2013-05-27 2016-04-13 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
WO2015006723A1 (en) 2013-07-12 2015-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
US20200208224A1 (en) 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
HRP20220496T1 (hr) 2014-09-26 2022-05-27 Janssen Pharmaceutica Nv Uporaba fgfr mutantnih genskih panela kod identifikacije pacijenata s rakom koji će reagirati na liječenje s inhibitorom fgfr
JOP20190190A1 (ar) 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
JP7051920B2 (ja) 2022-04-11
HUE058219T2 (hu) 2022-07-28
CR20170104A (es) 2017-05-31
JP2020124192A (ja) 2020-08-20
US20160090633A1 (en) 2016-03-31
ES2912567T3 (es) 2022-05-26
AU2015321626B2 (en) 2021-12-16
BR112017006088A2 (pt) 2017-12-19
CN107002141A (zh) 2017-08-01
MA40761B1 (fr) 2022-04-29
CN107002141B (zh) 2021-11-02
HRP20220496T1 (hr) 2022-05-27
TWI706136B (zh) 2020-10-01
SG11201702381QA (en) 2017-04-27
MY194567A (en) 2022-12-02
EP4063516A1 (en) 2022-09-28
CO2017003528A2 (es) 2017-07-11
IL251264A0 (en) 2017-05-29
WO2016048833A3 (en) 2016-05-19
UA122564C2 (uk) 2020-12-10
CN113957146A (zh) 2022-01-21
JP7558216B2 (ja) 2024-09-30
IL251264B (en) 2022-04-01
MA40761A (fr) 2017-08-01
CA2962075A1 (en) 2016-03-31
ECSP17025787A (es) 2018-07-31
TW201619609A (zh) 2016-06-01
PL3198033T3 (pl) 2022-08-29
EP3198033B1 (en) 2022-02-16
RS63178B1 (sr) 2022-06-30
KR20170062495A (ko) 2017-06-07
JP2022109910A (ja) 2022-07-28
JP2024112991A (ja) 2024-08-21
JO3681B1 (ar) 2020-08-27
US20240309463A1 (en) 2024-09-19
AU2025201448A1 (en) 2025-03-20
US20190078166A1 (en) 2019-03-14
EP3198033A2 (en) 2017-08-02
AU2021277633B2 (en) 2024-11-28
SMT202200177T1 (it) 2022-05-12
MX2017003954A (es) 2017-12-14
NI201700035A (es) 2017-06-22
AU2015321626A1 (en) 2017-04-06
GT201700059A (es) 2019-08-21
WO2016048833A2 (en) 2016-03-31
MX2022006536A (es) 2022-07-11
PT3198033T (pt) 2022-05-25
ZA201702899B (en) 2019-06-26
AU2021277633A1 (en) 2021-12-23
PH12017500556A1 (en) 2017-08-30
CY1125190T1 (el) 2024-12-13
JP6766037B2 (ja) 2020-10-07
KR102470456B1 (ko) 2022-11-23
SV2017005415A (es) 2017-07-03
MX392774B (es) 2025-03-24
NZ730886A (en) 2024-08-30
EA037920B1 (ru) 2021-06-07
LT3198033T (lt) 2022-05-10
SI3198033T1 (sl) 2022-06-30
AR102345A1 (es) 2017-02-22
DK3198033T3 (da) 2022-04-11
IL291633A (en) 2022-05-01
US12037644B2 (en) 2024-07-16
JP2017529090A (ja) 2017-10-05
KR20220162823A (ko) 2022-12-08
UY36325A (es) 2016-04-01

Similar Documents

Publication Publication Date Title
EA201790716A1 (ru) Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
PH12019502710A1 (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
MX2022014633A (es) Metodos para detectar norovirus.
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
MY195999A (en) Molecular Detection/Diagnosis Reagent for Tumor
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
MX2021007667A (es) Composiciones y metodos para detectar un contaminante biologico.
JOP20190199B1 (ar) استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EP3686290A3 (en) Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
WO2015120094A3 (en) Method of identifying tyrosine kinase receptor rearrangements in patients
MX388084B (es) Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
EP4407047A3 (en) Molecular detection of enterovirus and parechovirus
BR112015019425A2 (pt) Métodos e kits para identificar e ajustar desvio no sequenciamento de amostras de polinucleotídeos
JOP20210266A1 (ar) مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية
HK1250958A1 (zh) 用於治療癌症的組合物和方法
EA201992849A1 (ru) Ингибиторы fgfr2 для лечения холангиокарциномы
WO2014110230A3 (en) Methods for diagnosing cancer based on small nucleolar rna hbii-52
PL413907A1 (pl) Sposób wykrywania genetycznie uwarunkowanej zwiększonej predyspozycji do raka jelita grubego
PL408727A1 (pl) Zestaw diagnostyczny i sposób jednoczesnego wykrywania mutacji w obrębie genu NF1 dla grupy pacjentów z podejrzeniem choroby Recklinghausena
UA92246U (ru) Спектрофотометрический способ количественного определения зопиклона
UA96023U (ru) Способ прогнозирования сращивания перелома
UA96056U (ru) Способ прогнозирования сращивания перелома
UA94327U (ru) Способ прогнозирования несращения перелома